United States

Propeller Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Propeller Health Enters Japan with Digital Health Sensor for New Enerzair® and Atectura® Breezhaler® Asthma Medications

Lead Product(s): Indacaterol acetate,Glycopyrronium Bromide,Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Enerzair

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 26, 2020

Details:

Patients using Enerzair® and Atectura® Breezhaler® to manage their uncontrolled asthma in Japan will have the option to enroll in Propeller’s digital health platform to help manage their condition.

Lannett Company, Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Lannett Signs Agreement with Respirent Pharmaceuticals for Exclusive Distributor Of Generic Flovent® Diskus®

Lead Product(s): Fluticasone Propionate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Flovent Diskus

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Respirent Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 17, 2020

Details:

Lannett announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals.

TB Alliance

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis

Lead Product(s): Pretomanid,Bedaquiline,Linezolid

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PA-824

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

Details:

The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.

Janssen Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline) as Part of Combination Therapy

Lead Product(s): Bedaquiline

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB).

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Propeller Health

Propeller Health Enters Japan with Digital Health Sensor for New Enerzair® and Atectura® Breezhaler® Asthma Medications

Lannett Company, Inc.

Lannett Signs Agreement with Respirent Pharmaceuticals for Exclusive Distributor Of Generic Flovent® Diskus®

TB Alliance

TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis

Janssen Pharmaceutical

U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline) as Part of Combination Therapy